Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview

Kinnate Biopharma

15/03/2024 21:25

* Kinnate Biopharma Inc  KNTE.OQ   KNTE.O  is expected
to show no
change in quarterly revenue when it reports  results on March 18
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Kinnate Biopharma Inc is
for a
loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $2.50​, below​ its last closing price of $2.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.67       -0.67      -0.65     Beat    3.7
 Jun. 30 2023  -0.78       -0.75      -0.68     Beat    9.3
 Mar. 31 2023  -0.70       -0.73      -0.73     Met     0​
 Dec. 31 2022              -0.72      -0.72     Met     -0.6
 ​​Sep.        -0.60       -0.61      -0.70     Missed  -15.2
 30 2022                                                
 Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.9​
 Mar. 31 2022  -0.62       -0.61      -0.61     Met     -0.5
 Dec. 31 2021  -0.60       -0.59      -0.60     Missed  -2.2
 This summary was machine generated March 15 at 21:25 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)